Skip to main content

Bipolar Disorder: Assessment for diabetes

CBE ID
0003
1.5 Project
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description

Percentage of patients treated for bipolar disorder who are assessed for diabetes within 16 weeks after initiating treatment with an atypical antipsychotic agent.

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      1.20 Types of Data Sources
      1.14 Numerator

      Assessment for diabetes must include documentation of one of the following:
      • Reference in chart that test was ordered and results or information about results was obtained
      OR
      • Lab results filed in chart or available in patient’s electronic medical record
      Reference: Tests used to screen/assess for diabetes:
      Preferred Fasting plasma glucose; Non-fasting plasma glucose; Glucose tolerance Also Accepted: Glycosylated hemoglobin (Hb A1c; glycated hemoglobin) Random glucose AND

      Timeframe: Test results/information from test conducted within 16 weeks after the initiation of a second generation atypical antipsychotic agent
      OR
      Measurement EXCLUSION FROM COMPLIANCE Issues
      Numerator criteria not applicable and exclusion from compliance as stated below:
      1.Dcumentation by physician that test was not clinically indicated for this patient
      OR
      2Documentation that test was requested but patient failed to comply with request to obtain test

      1.15 Denominator

      Patients 18 years of age or older with an initial or new episode of bipolar disorder
      AND
      Documentation of a diagnosis of bipolar disorder; to include at least one of the following:
      • Codes 296.0x; 296.1x; 296.4x; 296.5x; 296.6x; 296.7; 296.80; 296.81; 296.82; 296.89; 301.13 documented in body of chart, such as a pre-printed form completed by a clinician and/or codes documented in chart notes/forms
      OR
      • Diagnosis or Impression or “working diagnosis” documented in chart indicating bipolar disorder
      OR
      • Use of a screening/assessment tool for bipolar disorder with a score or conclusion that patient has bipolar disorder and documentation that this information is used to establish or substantiate the diagnosis
      AND
      Documentation of treatment with an atypical antipsychotic agent. (See reference list below)
      Note: It is not the intent to indicate preferred pharmacotherapy. The reference list is inclusive of those atypical antipsychotic medications that are reasonably construed to be appropriate in accordance with current guidelines. (Reference list of medications also included in data collection form)
      Atypical Antipsychotic Agents
      • aripiprazole
      • quetiapine
      • clozapine
      • risperidone
      • olanzapine
      • ziprasidone
      • olanzapine-fluoxetine (combination)

      None. New diagnosis” or a “new episode,” is defined as cases where the patient has not been involved in active treatment for 6 months. Active treatment includes being hospitalized or under the out-patient care of a physician.

      Exclusions

      None.

      Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Behavioral Health Project 2013-2015
      Initial Endorsement
      Last Updated
      Removal Date
      Steward Organization
      Center for Quality Assessment and Improvement in Mental Health
      Steward POC email
                Public Comments